On November 5, 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, reported that Pierre Bélichard, CEO, and Christelle Dumoussaud, CFO, will present an overview of the Company and participate in 1-on-1 meetings with institutional investors at the following events (Press release, Enterome, NOV 5, 2024, View Source [SID1234647723]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Inv€$tival Showcase in London, UK, November 18, 2024
Enterome’s presentation is scheduled at 13:30 GMT on the "Biotech Late Growth" stage.
Jefferies’ London Healthcare Conference, UK, November 19-21, 2024
43rd J.P. Morgan Annual Healthcare Conference in San Francisco, USA,
January 13-16, 2025
Enterome’s management team will also attend the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Conference, from December 7-10, 2024, in San Diego, California, and will be available to discuss the latest clinical advances from the company’s onco-hematology pipeline.